Medicamen Biotech
- Market Cap
- ₹392 Cr
- P/E
- 33.88
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 5.82%
- Debt to Equity
- 0.15
- EPS (TTM)
- ₹8.53
- Book Value
- ₹207.92
- Market Cap
- ₹392 Cr
- P/E (TTM)
- 33.88
- P/B
- 1.39
- ROE
- 3.95%
- Dividend Yield
- 0.34%
- EBITDA
- ₹22.70 Cr
- 52W High
- ₹447.65
- 52W Low
- ₹212.40
- Day Range
- ₹289.00 – ₹298.80
- Volume
- 9,386
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.10 | 41.23 | 4,52,059 | 5.06 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,132.00 | 87.87 | 2,95,520 | 16.42 | 0.26% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,648.60 | 77.12 | 1,76,818 | 9.62 | 0.81% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,320.00 | 93.55 | 1,25,352 | 20.68 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,203.50 | 28.71 | 1,20,050 | 4.32 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,380.80 | 41.16 | 1,15,253 | 2.97 | 0.58% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,390.50 | 38.76 | 1,12,333 | 3.17 | 0.93% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 289.00 | 33.88 | 392 | 1.39 | 0.36% | 3.95% | 5.82% | 210 | 12 | |
| Median 8 companies | 1,637.30 | 41.19 | 1,22,701 | 4.69 | 0.47% | 16.25% | 16.65% | 22,770 | 2,808 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 36
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 40
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 74
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 60
- Good
- Solvency, leverage, coverage 9% weight
- Momentum
- 69
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 57
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is expected to give good quarter
- Promoter holding has increased by 2.11% over last quarter.
Weaknesses
4- The company has delivered a poor sales growth of 11.9% over past five years.
- Company has a low return on equity of 4.23% over last 3 years.
- Dividend payout has been low at 14.5% of profits over last 3 years
- Company has high debtors of 151 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 3 | 13 |
| Oscillators | Neutral | 3 | 3 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Neutral
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 59.22
- Neutral
- MACD (12,26,9)
- −1.36
- Bullish
- SMA (50)
- 292.44
- Bullish
- SMA (200)
- 272.72
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 5Y | +11.87% |
|---|---|
| 3Y | +11.98% |
| 1Y | +21.47% |
| TTM | +27.48% |
Net profit
| 5Y | −3.58% |
|---|---|
| 3Y | −12.64% |
| 1Y | +42.86% |
| TTM | +41.72% |
Operating cash flow
| 5Y | Turned negative |
|---|---|
| 3Y | Outflow widened by ₹27 Cr |
| 1Y | Outflow widened by ₹25 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −7.09 pp |
|---|---|
| 3Y | −6.41 pp |
| 1Y | +2.02 pp |
| TTM | +1.84 pp |
Revenue by year
| Mar 2019 | ₹123 Cr |
|---|---|
| Mar 2020 | ₹125 Cr |
| Mar 2021 | ₹113 Cr |
| Mar 2022 | ₹115 Cr |
| Mar 2023 | ₹141 Cr |
| Mar 2024 | ₹179 Cr |
| Mar 2025 | ₹163 Cr |
| Mar 2026 | ₹198 Cr |
Net profit by year
| Mar 2019 | ₹12.00 Cr |
|---|---|
| Mar 2020 | ₹13.00 Cr |
| Mar 2021 | ₹12.00 Cr |
| Mar 2022 | ₹15.00 Cr |
| Mar 2023 | ₹15.00 Cr |
| Mar 2024 | ₹9.00 Cr |
| Mar 2025 | ₹7.00 Cr |
| Mar 2026 | ₹10.00 Cr |
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.54 | 46.5 | 47.32 | 43.05 | 44.74 | 45.14 | 29.61 | 43.04 | 47.17 | 46.91 | 60.65 | 47.9 | 54.83 |
| Expenses | 38.89 | 41.6 | 41.57 | 39.6 | 39.43 | 38.43 | 31.22 | 38.43 | 42.01 | 42.53 | 55.22 | 43.57 | 46.15 |
| Operating Profit | 4.65 | 4.9 | 5.75 | 3.45 | 5.31 | 6.71 | −1.61 | 4.61 | 5.16 | 4.38 | 5.43 | 4.33 | 8.68 |
| OPM % | 10.68% | 10.54% | 12.15% | 8.01% | 11.87% | 14.86% | −5.44% | 10.71% | 10.94% | 9.34% | 8.95% | 9.04% | 15.83% |
| Other Income | 0.55 | 0.83 | 0.57 | 0.59 | 0.29 | 0.14 | 5.23 | 0.47 | 0.37 | 0.53 | 1.74 | 0.86 | 0 |
| Interest | 0.91 | 0.65 | 1.89 | 0.71 | 1.04 | 0.76 | 0.65 | 1.15 | 0.99 | 0.97 | 0.38 | 0.83 | 1.69 |
| Depreciation | 1.82 | 1.8 | 1.77 | 1.77 | 2.61 | 2.21 | 0.48 | 1.8 | 1.86 | 1.83 | 1.73 | 1.79 | 1.87 |
| PBT | 2.46 | 3.27 | 2.66 | 1.56 | 1.96 | 3.88 | 2.49 | 2.13 | 2.68 | 2.11 | 5.06 | 2.57 | 5.12 |
| Tax % | 39.68% | 38.11% | 22.93% | 48.72% | 53.85% | 24.74% | 25.3% | 24.88% | 21.27% | 22.27% | 12.06% | 28.4% | 19.53% |
| Net Profit | 1.48 | 2.03 | 2.04 | 0.8 | 0.9 | 2.92 | 1.87 | 1.6 | 2.11 | 1.64 | 4.45 | 1.85 | 4.12 |
| EPS (₹) | 1.19 | 1.90 | 1.68 | 1.06 | 1.15 | 2.73 | 1.90 | 1.59 | 1.97 | 1.61 | 2.85 | 1.56 | 2.51 |
| YoY Sales growth | 29.85 | 30.69 | 22.37 | 2.65 | 2.76 | −2.92 | −37.43 | −0.02 | 5.43 | 3.92 | 105 | 11.29 | 16.24 |
Profit & Loss
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 125 | 113 | 115 | 141 | 179 | 163 | 198 | 210 |
| Expenses | 105 | 106 | 93 | 91 | 117 | 156 | 148 | 177 | 187 |
| Operating Profit | 17 | 20 | 20 | 24 | 24 | 24 | 14 | 21 | 23 |
| OPM % | 14% | 16% | 17% | 21% | 17% | 13% | 9% | 10% | 11% |
| Other Income | 4 | 2 | 1 | 2 | 2 | 2 | 6 | 3 | 3 |
| Interest | 1 | 1 | 2 | 2 | 3 | 6 | 4 | 5 | 4 |
| Depreciation | 2 | 2 | 3 | 6 | 6 | 7 | 7 | 7 | 7 |
| PBT | 18 | 18 | 16 | 18 | 17 | 13 | 10 | 12 | 15 |
| Tax % | 31% | 26% | 26% | 18% | 14% | 27% | 34% | 18% | — |
| Net Profit | 12 | 13 | 12 | 15 | 15 | 9 | 7 | 10 | 12 |
| EPS (₹) | 10.28 | 10.88 | 9.93 | 12.20 | 11.73 | 8.60 | 5.59 | 7.11 | 8.53 |
| Div. Payout % | 10% | 5% | 10% | 8% | 9% | 12% | 18% | 14% | — |
| Sales growth | — | 2 | −10 | 2 | 22 | 27 | −9 | 22 | 27 |
Balance Sheet
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 14 |
| Reserves | 75 | 109 | 121 | 134 | 181 | 194 | 200 | 262 | 268 |
| Borrowings | 12 | 11 | 19 | 26 | 26 | 31 | 34 | 49 | 41 |
| Other Liabilities | 38 | 49 | 42 | 53 | 59 | 56 | 50 | 47 | 37 |
| Total Liabilities | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 | 360 |
| Fixed Assets | 24 | 34 | 90 | 92 | 93 | 92 | 87 | 85 | 82 |
| CWIP | 15 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 97 | 107 | 104 | 133 | 186 | 203 | 210 | 287 | 278 |
| Total Assets | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 | 360 |
Cash Flow
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 4 | 13 | 13 | 4 | −6 | −7 | −8 | −33 |
| Investing | −15 | −37 | −18 | −8 | −6 | −6 | −1 | −3 |
| Financing | −4 | 19 | 6 | 4 | 29 | 6 | −1 | 64 |
| Net Cash Flow | −14 | −5 | 1 | 0 | 17 | −6 | −11 | 28 |
| Free Cash Flow | −11 | −25 | −5 | −4 | −13 | −13 | −10 | −38 |
| CFO/EBITDA | 48 | 88 | 88 | 30 | −13 | −16 | −47 | −150 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 129 | 145 | 170 | 200 | 169 | 112 | 155 | 151 |
| Inventory Days | 67 | 78 | 27 | 188 | 228 | 234 | 268 | 251 |
| Days Payable | 134 | 173 | 169 | 302 | 241 | 154 | 184 | 144 |
| Cash Conversion Cycle | 62 | 51 | 28 | 86 | 156 | 193 | 239 | 259 |
| Working Capital Days | 116 | 130 | 126 | 147 | 156 | 123 | 186 | 193 |
| ROCE % | — | 16% | 13% | 12% | 10% | 8% | 6% | 6% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Medicamen Biotech insights
70 extracted metrics across FY10–FY27.
Documents
- 1 Dec 2025
- 4 Sep 2024
- 9 Aug 2024
- 7 Jun 2023
- 29 Mar 2022
- General announcements 26 Oct 2026
Frequently Asked Questions about Medicamen Biotech
What does Medicamen Biotech Ltd do?
Where is Medicamen Biotech Ltd (MEDICAMEQ) listed?
Which sector does Medicamen Biotech Ltd belong to?
What is the market capitalisation of Medicamen Biotech Ltd?
What is the PE ratio of Medicamen Biotech Ltd?
What is the 52-week high and low of Medicamen Biotech Ltd?
Does Medicamen Biotech Ltd pay dividends?
What is the Return on Equity (ROE) of Medicamen Biotech Ltd?
Company Information
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDICAMEQ.md for Medicamen Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.